By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Y17 M22, Life Science ETH/Uni
Winterthurerstrasse 190
Zurich    CH-8057  Switzerland
Phone: 41-44-6356033 Fax: 41-44-6356896



Start Up

Company News
Covagen Initiates Phase 1b/2a Study Of Bispecific Anti-TNF/IL-17A Fynomab COVA322 5/5/2014 8:25:52 AM
Covagen Adds Baxter Ventures As Investor 2/19/2014 10:23:10 AM
Covagen Locks In $47.2 Million Series B 12/10/2013 7:06:49 AM
Covagen And Tanabe Research Laboratories U.S.A., Inc. Expand Strategic Research Collaboration For Development Of Bispecific FynomAbs 11/21/2013 6:37:21 AM
Covagen Names Elias Papatheodorou Chief Business Officer 4/15/2013 6:25:34 AM
Covagen Inks $146 Million Pact With Mitsubishi Tanabe Pharma Corporation 10/17/2012 7:20:48 AM
Covagen Nominates Bispecific TNF/IL-17A Inhibitor as Drug Candidate to Enter Preclinical Development 12/12/2011 8:47:56 AM
Sir Gregory Winter Joins Covagen's Scientific Advisory Board 9/20/2011 10:16:23 AM
Covagen Nominates Franz Hefti as New Member of the Board of Directors 5/16/2011 11:14:54 AM
Covagen Nominates Frank Walsh as Executive Chairman and Appoints Mathias Locher as Chief Development Officer 3/7/2011 10:37:01 AM